Press Releases

Search

January 13, 2025
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

•    Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025 •    Plan to report top-line results from pivotal PEAK Phase 3 trial in 2 nd -line GIST patients by end of 2025 •    Plan to report top-line results from registration-directed APEX trial

Read More
January 8, 2025
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present
Read More


The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.
Scroll to Top